Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Revvity Inc (RVTY) Price & Performance

Allbirds IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Revvity Inc — how do they compare? Allbirds Inc trades at $3.03 (market cap $25.89M), while Revvity Inc trades at $111.51 (market cap $12.41B). The key difference: Revvity Inc is far larger — about 479.3× Allbirds Inc's market cap, and Revvity Inc pays a 0.25% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.

BIRDRVTY
Market Cap
$25.89M$12.41B
Sector
Consumer CyclicalTechnology
52-Week High
$16.99$117.75
52-Week Low
$2.39$82.26
Enterprise Value
$44.76M$14.90B
Dividend Yield
0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $3.00, down 4.15% today, amid a complete business pivot from footwear to AI infrastructure. The stock shows a bearish technical trend with all moving averages signaling sell, while oscillators suggest potential oversold conditions. Fundamentally, the company reports declining revenue ($152M in 2025) and persistent losses (-$77M net income), though it maintains a low P/S ratio of 0.17. Recent news highlights the strategic shift, including a rebrand to Smartbird and appointment of a new CEO from Amazon Web Services (Reuters, June 17, 2026).

The outlook is highly speculative, driven by the unproven AI strategy rather than current fundamentals. Investment opportunity lies in potential AI sector growth, but risks include execution challenges, cash burn (-$40M net cash flow in 2025), and intense competition. Analysts are cautious with 79% hold ratings, reflecting uncertainty about the pivot's success. Shareholders face volatility as the company transitions from a tangible product business to technology infrastructure.

Revvity Inc

RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.

The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY